#United States #New York #Securities Fraud #Rocket Pharmaceuticals #RCKT

Investors of Rocket Pharmaceuticals: Important Class Action Lawsuit Update

In a significant development for shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), Rosen Law Firm has issued a reminder to investors who purchased securities within a specified period that they may be eligible to participate in a class-action lawsuit. The timeline for this opportunity spans from September 17, 2024, to May 26, 2025. If you are among those who experienced losses exceeding $100,000, your action is required soon as the deadline for lead plaintiff applications is set for August 11, 2025.

What You Need to Know

Participating in this lawsuit offers investors a chance to seek compensation without the burden of upfront fees due to a contingency fee arrangement structured by the law firm. To join the class action, individuals are encouraged to visit Rosen Legal’s submission page or directly contact Phillip Kim, Esq. at 866-767-3653, or via email at [email protected]

Nature of the Complaint

The legal action revolves around allegations that Rocket Pharmaceuticals provided misleading information during the class period. Specifically, the lawsuit claims the defendants engaged in practices including:
1. A misrepresentation of the effectiveness of RP-A501, leading investors to believe it was far more beneficial than it proved to be.
2. Modifications made to the clinical trial protocols of RP-A501 that introduced a new immunomodulatory agent, which posed increased risks of Serious Adverse Events (SAEs) to patients.
3. An overstatement of RP-A501’s safety profile, clinical results, and potential for regulatory approval and market success.

These claims suggest that defendants’ statements were materially misleading at all times relevant to the class period. Once these realities were disclosed to the market, affected investors experienced significant financial losses.

Next Steps for Investors

If you believe you qualify to join this lawsuit, taking prompt action is crucial. The Rosen Law Firm, known globally for representing investor rights and with a track record of achievement in securities class actions, stresses the importance of selecting experienced and highly competent legal counsel. Unlike many firms that function merely as intermediaries, Rosen Law has consistently led efforts in securing investor settlements, including a notable case against a Chinese company, which resulted in record results previously.

The firm ranked as the top by ISS Securities Class Action Services for the number of settlements in 2017, placing within the top four every year thereafter, recovering over hundreds of millions for investors. For instance, in 2019, they successfully secured more than $438 million for clients, a testament to their capability. Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, attesting to their solid reputation in litigating securities class actions.

Important Information and Contact Details

While no class has been certified yet, investors should understand that they must retain counsel to be represented, or they may choose to remain absent from the class and still potentially share in any recovery without being lead plaintiffs. Thus, those interested in participating should evaluate their legal representation options carefully.

You can stay updated with any developments posted by following Rosen Law Firm on LinkedIn, Twitter, or Facebook. This is critical for keeping abreast of case updates and further legal advice.

Consider this your opportunity to reclaim losses suffered due to potential securities fraud perpetrated by Rocket Pharmaceuticals. Ensure you take action before the approaching deadline, as time is of the essence in participating in this significant class action.

Disclaimer: This is attorney advertising; prior results do not guarantee a similar outcome. For further inquiries, please reach out directly to the listed contact details for the Rosen Law Firm.